On August 3, 2015 the New York Times published an article about the use of IP chemotherapy in the treatment of ovarian cancer. Our CEO, Calaneet Balas joined with Ovarian Cancer Research Fund CEO, Audra Moran, to write a response to the New York Times. Click the plus sign to see their Letter to the Editor.
(8/12/15) In response to the article “An Ovarian Cancer Treatment, Recommended Since 2006, is Found to be Underused,“ published in the Health section of The New York Times on August 3, 2015, OCRF … Continued
Gynecologic Cancer Patients to Receive Support in 6 New Locations WEST CHESTER, Pa (August 10, 2015) —Ovarian Cancer Research Fund (OCRF) and QVC today announced six new Woman to Woman … Continued
(July 30, 2015) Recurrent ovarian cancer patients have more hope today, thanks to OCRF-funded research by David Pepin, PhD at Massachusetts General Hospital. Dr. Pepin and his colleagues found that … Continued
(July 23, 2015) New OCRF-funded research demonstrates that combining a PARP-inhibitor with immune therapy results in tumor rejection and long-term survival in a mouse model of BRCA1-deficient ovarian cancer. The … Continued
QVC and Ovarian Cancer Research Fund Joining Forces for “QVC Presents Super Saturday LIVE” Broadcast WEST CHESTER, Pa. (July 21, 2015) – Help advance the fight against ovarian cancer with … Continued
NASCAR’s Martin Truex Jr.’s girlfriend Sherry Pollex goes to Capitol Hill to advocate for affordable therapy costs, ovarian cancer research funding Pollex, Ovarian Cancer National Alliance support Cancer Treatment Parity … Continued
WORLD FAMOUS DESIGNER GARAGE SALE SPONSORED BY QVC SATURDAY, JULY 25TH IN WATER MILL, NY NEW YORK, N.Y. – July 7, 2015 – Donna Karan and Kelly Ripa will host … Continued
(6/19/15) OCRF recently welcomed three new members to the Scientific Advisory Committee (SAC), our world-class group of leaders in the ovarian cancer field who review and approve all OCRF research … Continued
(June 19, 2015) In a recent study, funded in part by OCRF grants to Dr. Simon Gayther and Dr. Andrew Berchuck, researchers have made important breakthroughs toward understanding the risk … Continued
Introducing the 2015 Ovarian Cancer National Conference Rosalind Franklin Excellence in Ovarian Cancer Research Award winner: Beth Karlan, MD. The Rosalind Franklin Excellence in Ovarian Cancer Research Award is named for the molecular biologist Dr. Rosalind Elsie Franklin, who played a vital role in discovering the structure of DNA. Her career was cut short in 1958 when she died of ovarian cancer at age 37. Throughout her life, she was a committed researcher; this award honors an individual who continues her legacy of excellence. Beth Karlan, MD is the Director of the Cedars-Sinai Women’s Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Director of the Division of Gynecologic Oncology in the Department of Obstetrics and Gynecology, and Director of the Gilda Radner Hereditary Cancer Program. Click the plus sign to read more.
Ovarian Cancer Research Fund, Ovarian Cancer National Alliance and National Ovarian Cancer Coalition Team-Up to Fund Game-Changing Ovarian Cancer Research Today the members of the new Stand Up To Cancer-Ovarian … Continued
Get email updates about research news, action alerts, and ways to join the fight.
